Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/ijms23063041
Keywords
antibody-drug conjugate; radiation therapy; therapeutic target; radiation-inducible
Funding
- Medical Guidance Systems LLC, St. Louis, Missouri, USA
- NIH [R44CA210687, R41CA233020]
- Elsa U. Pardee Foundation [K22CA234404]
Ask authors/readers for more resources
Therapeutic antibodies are effective in treating advanced-stage cancer by activating T-lymphocytes and targeting cancer-specific antigens. Additionally, using radiation therapy can enhance the efficacy of these antibodies and antibody-drug conjugates in cancer treatment.
Therapeutic antibodies used to treat cancer are effective in patients with advanced-stage disease. For example, antibodies that activate T-lymphocytes improve survival in many cancer subtypes. In addition, antibody-drug conjugates effectively target cytotoxic agents that are specific to cancer. This review discusses radiation-inducible antigens, which are stress-regulated proteins that are over-expressed in cancer. These inducible cell surface proteins become accessible to antibody binding during the cellular response to genotoxic stress. The lead antigens are induced in all histologic subtypes and nearly all advanced-stage cancers, but show little to no expression in normal tissues. Inducible antigens are exploited by using therapeutic antibodies that bind specifically to these stress-regulated proteins. Antibodies that bind to the inducible antigens GRP78 and TIP1 enhance the efficacy of radiotherapy in preclinical cancer models. The conjugation of cytotoxic drugs to the antibodies further improves cancer response. This review focuses on the use of radiotherapy to control the cancer-specific binding of therapeutic antibodies and antibody-drug conjugates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available